Surgical strategy for atrial functional mitral regurgitation with atrial fibrillation

Chunrong Bao, MD1, Ke Wei, MD1, Dongfang Zhao, MD2, Junwen Zhang, MD1, Ju Mei,

MD1, Nan Ma, MD1

1. Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine,

Shanghai Jiaotong University, China

2. NSW Health Pathology, Sydney, NSW, Australia

Chunrong Bao and Ke Wei are co-first authors.

Correspondence to:

Ju Mei, Professor

Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University

1665, Kongjiang Road, Yangpu District, Shanghai, 200092

Tel: +86 13801669185

Email: mei_ju63@126.com

Nan Ma, Professor

Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University

1665, Kongjiang Road, Yangpu District, Shanghai, 200092

Tel: +86 15001994818

Email: manancts@sina.com

Running head : Surgical strategy for AFMR with AF

Disclosures: The authors have declared that no conflict of interest exists.

Funding: The work was sponsored by National Natural Science Foundation of

China (grant number: 82170313)

1 Abstract

2 Background

3 With the growing prevalence of atrial fibrillation (AF), atrial functional mitral regurgitation (AFMR) combined with AF is expected to become a common clinical issue. We 4 5 have summarized various surgical treatment strategies based on the degree of mitral regurgitation (MR) alongside rhythm control therapy for patients with AFMR and AF. 6 7 Methods 8 This retrospective study included 145 patients with AF and MR from January 2017 to January 2023. 33 patients with AF and moderate AFMR were designated as the moderate 9 atrial regurgitation (MAR) group. 56 patients with AF and severe AFMR were designated as 10 the severe atrial regurgitation (SAR) group. The remaining 56 patients with AF and severe 11 primary MR were designated as the severe primary regurgitation (SPR) group. All patients in 12 13 the MAR group underwent thoracoscopic AF procedure via a unilateral approach. Patients in 14 the SAR and SPR groups underwent mitral valvuloplasty plus the Cox Maze IV procedure

16 Results

15

Twenty-three patients maintained sinus rhythm (SR) following thoracoscopic AF
procedure in the MAR group at average 2.6±1.1 years follow-up. The degree of regurgitation
improved in 26 patients, remained unchanged in 6 patients, and worsened in 1 patient. SR
maintenance benefits MR reduction (P<0.0001) compared to the non-SR patients. There was
no significant difference in the rate of SR maintenance following mitral valvuloplasty plus
CMP IV between SAR (43 patients, 79.6%) and SPR (49 patients, 87.5%) groups. At the last
follow-up, echocardiography in the SAR group showed 47 cases with no mitral regurgitation,

(CMP IV). Descriptive characteristics and outcomes were analysed.

24	4 cases with mild regurgitation, and 1 case with moderate regurgitation. The left atrial				
25	diameter in the SAR group remained larger than in the SPR group (P<0.001).				
26	Conclusions				
27	Rhythm control therapy is the cornerstone treatment for AFMR patients with AF.				
28	Thoracoscopic AF procedure is effective and minimally invasive for moderate AFMR				
29	patients with AF. For severe AFMR patients with AF, we recommend CMP IV plus mitral				
30	valvuloplasty for safety and effectiveness.				
31	Keywords: atrial functional mitral regurgitation; atrial fibrillation; thoracoscopic				
32	ablation; Cox-Maze IV procedure;				
33					
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					

45 **Introduction**

Atrial functional mitral regurgitation (AFMR) is receiving increasing attention as a type 46 of functional mitral regurgitation (MR) secondary to structural or functional abnormalities of 47 the left atrium¹. Clinically, it is more common in patients with non-paroxysmal atrial 48 fibrillation (AF)^{2,3}. Epidemiological studies have shown that the incidence of moderate to 49 severe AFMR in patients with persistent AF is 4-8%, rising to 28% in those with AF lasting 50 more than 10 years ^{4,5}. With the growing prevalence of AF, AFMR combined with AF is 51 52 expected to become a common clinical issue. However, there is still a lack of research (particularly surgical studies) addressing this combination.^{6,7}. Utilising a single treatment 53 modality for MR with functional regurgitation is often unsatisfactory. Results from catheter 54 ablation studies suggest that restoring sinus rhythm (SR) can reduce valve regurgitation 55 through cardiac remodelling. However, the success rate of catheter ablation and the certainty 56 of cardiac remodelling in reducing regurgitation remain concerning. We have summarized 57 58 data from AFMR patients with AF treated at our centre, employing different treatment strategies based on the degree of MR alongside rhythm control therapy. 59

60 Methods

61 *Patient Selection & Characteristics*

This retrospective cohort study included 145 patients with AF and MR treated at the Department of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, from January 2017 to January 2023. Thirty-three patients with AF and moderate AFMR were designated as the moderate atrial regurgitation (MAR) group. 56 patients with AF and severe AFMR were designated as the severe atrial regurgitation (SAR) group. The remaining 56 patients with AF and severe primary MR were designated as the severe primary regurgitation (SPR) group. All patients received appropriate

rate control, anti-hypertensives, and diuretic therapy before preoperative cardiac echo
examination. The diagnostic criteria for AFMR are based on relevant literature: exclusion of
organic mitral valve disease, left ventricular ejection fraction (LVEF) ≥50%, no abnormal left
ventricular wall systolic activity, and left ventricular end-diastolic diameter <55 mm ^{8,9}. The
degree of mitral regurgitation was diagnosed according to guidelines and confirmed by two
physicians.

The MAR group included 20 males and 13 females, with an average age of 70.27±6.46 75 years. Four cases had persistent AF and 29 had long-term persistent AF. The history of AF 76 averaged 7.12±4.83 years, and the median CHA2DS2–VASc score was 3 points (0-6). 77 Preoperative echocardiography showed moderate MR in 33 cases. The left atrium diameter 78 was 48.15±4.19 mm, the left ventricular end-diastolic diameter was 49.91±3.29 mm, and 79 LVEF was 56.39±4.90%. Preoperative cardiac function was NYHA grade I in 1 case, grade II 80 in 17 cases, grade III in 12 cases, and grade IV in 3 cases. There were 22 patients with 81 82 tricuspid regurgitation, 8 with coronary heart disease, 19 with hypertension, 10 with diabetes, and 3 with a history of stroke. Three patients had undergone catheter ablation. Baseline 83 characteristics of MAR group are described in Table 1. 84

85 In the SAR group, there were 37 males and 19 females, with an average age of 70.54 \pm 5.91 years. All patients had long-term persistent AF with a history of 6.10 \pm 4.32 years. 86 87 The median CHA2DS2–VASc score was 3 points (3-4). Thirty-eight patients had moderate or above tricuspid regurgitation, 15 had coronary heart disease, 42 had hypertension, 15 had 88 diabetes, and 7 had a history of stroke. Four patients had a history of catheter ablation. 89 90 In the SPR group, there were 36 males and 20 females, with an average age of 66.43±6.39 years. Forty-four patients had long-term persistent AF, and 12 had persistent AF, 91 with an AF history of 4.44±2.58 years. The median CHA2DS2–VASc score was 2 points (2-92

3). There were 23 patients with moderate or above tricuspid regurgitation, 6 with coronary
heart disease, 27 with hypertension, 9 with diabetes, and 4 with a history of stroke. One
patient had a history of catheter ablation. Baseline characteristics of both groups are
described in Table 1.

97 Surgical Procedures

98 All patients in the MAR group underwent thoracoscopic AF procedure via a unilateral approach as previously described [5, 6]. After anesthesia, patients were positioned in the right 99 lateral decubitus position. Chest wall incisions were made at the 6th, 7th, 8th, or 6th, 8th, and 100 8th intercostal spaces near the inferior angle of the left scapula. The ablation routes included 101 ablation of the left and right pulmonary veins, the posterior wall of the left atrium, the 102 ablation line from the left pulmonary vein to the anterior mitral annulus (Dallas lesion), the 103 104 ablation line from the left pulmonary vein to the resection edge of the left atrial appendage, and the ablation line between the two inferior pulmonary veins. The left atrial appendage was 105 either resected with a stapler or clamped with an atrial appendage clip. Marshall's ligament 106 107 and epicardial autonomic ganglia were ablated by ablation pen. If AF could not be terminated after all steps, cardioversion was performed. 108

Patients in the SAR and SPR groups underwent mitral valvuloplasty plus the Cox Maze 109 IV procedure (CMP IV). These procedures were performed under general anesthesia and 110 extracorporeal circulation. A minimally invasive approach was used to establish 111 extracorporeal circulation through the femoral artery and vein, with a small incision made in 112 113 the fourth intercostal space on the right chest wall. All mitral annuloplasties were performed with a prosthetic ring. Additional techniques included artificial chordae, partial excision of 114 the posterior leaflets, junctional suturing, and edge-to-edge suturing. If mitral annuloplasty 115 116 failed, mitral valve replacement was performed. CMP IV included standard ablation routes

for both the left and right atria, completed with a bipolar clamp, with isthmus ablation
supplemented by cryoenergy. The left atrial appendage was resected or sutured in a doublelayered linear fashion. Concomitant procedures included tricuspid valvuloplasty, coronary
artery bypass grafting.

121 Postoperative Care and Follow-up

122 Postoperatively, all patients received anticoagulation therapy with warfarin. If patient's heart rate exceeded 70 beats/min, oral amiodarone would be administered for 3 months. 123 124 Patients unable to maintain SR were treated with rate control. Recurrent AF was managed with cardioversion under adequate anticoagulation. Follow-up was conducted through 125 outpatient visits and telephone calls, including symptom evaluation and 24-hour dynamic 126 electrocardiograms at 3, 6, and 12 months, and every 6 months thereafter. Any documented 127 atrial tachyarrhythmia episodes lasting 30 seconds or longer were considered a recurrence 128 129 after a 3-month blanking period. Postoperative mitral valve function was assessed by echocardiography at 3, 6, and 12 months, and at least annually thereafter. 130

131 Statistical Analysis

Statistical analysis was performed using R (version 4.3.2). Measurements are expressed 132 as mean \pm standard deviation and compared using the t-test. Count data are expressed as rates 133 (percentages) and compared using Fisher's exact test. Kaplan-Meier (KM) curve was utilized 134 to analyze the success rates of AF treatments, while differences in success rates across groups 135 136 were assessed using the log-rank test, with a P-value of less than 0.05 considered statistically significant. Left atrial diameter values over time are shown in box plots, with median, 137 quartiles, and outliers. Differences were tested using repeated measures ANOVA. Changes 138 in MR severity are displayed in stacked bar charts, indicating patient counts and percentages. 139

Differences across stages were analyzed using Chi-square tests, with statistical significance
set at P<0.05. Factors associated with recurrence following AF ablation were identified
through an extensive review of the literature and previous experiences, and included in a
multivariate regression model following univariate analysis where a P-value less than 0.1 was
significant. A multivariate Cox proportional hazards regression model was employed to
evaluate risk factors for AF recurrence, providing a comprehensive analysis of potential
predictors.

147 *Ethical review*

This study has been approved by the Medical Ethics Committee of Xinhua Hospital
Affiliated to Shanghai Jiaotong University School of Medicine, and informed consent was
obtained from all participants.

151 **Results**

152 *Clinical Outcomes of AF Combined with Moderate AFMR*

Thoracoscopic AF procedure via a unilateral approach was successfully performed in all 153 patients in the MAR group. There was no conversion to thoracotomy and no perioperative 154 mortality. No blood products were transfused, and no serious postoperative complications 155 occurred. SR was maintained in 30 patients (90.9%) at discharge. Echocardiography before 156 discharge showed no mitral regurgitation in 18 cases, mild mitral regurgitation in 10 cases, 157 and moderate mitral regurgitation in 4 cases. The left atrium diameter (47.06±3.99 mm), left 158 ventricular end-diastolic diameter (49.58±3.16 mm), and LVEF (55.73±5.40%) were not 159 statistically different from pre-procedure measurements. 160

161	The last follow-up was in June 2023, with follow-up durations ranging from 1 to 6 years				
162	(average: 2.6±1.1 years). Twenty-three patients (69.70%) maintained SR, confirmed by 24-				
163	hour electrocardiography. The Kaplan-Meier curve illustrating freedom from AF recurrence				
164	is shown in Figure 1A. At the last follow-up, 17 patients had no mitral regurgitation, 9 had				
165	mild mitral regurgitation, 6 had moderate mitral regurgitation, and 1 had severe mitral				
166	regurgitation. The degree of regurgitation improved in 26 patients compared to pre-surgery				
167	levels, remained unchanged in 6 patients, and worsened in 1 patient. The left atrium diameter				
168	(46.42±4.40 mm), left ventricular end-diastolic diameter (49.94±3.32 mm), and LVEF				
169	(58.64±3.88%) were not statistically different from pre-procedure measurements.				
170 171	Effects of Rhythm Control on Cardiac Remodeling and Mitral Regurgitation in the MAR Group				
172	Patients in the MAR group were divided into two cohorts based on their ability to				
173	maintain SR post-surgery. SR maintenance benefits MR reduction (P<0.0001) compared to				
174	the non-SR patients (Figure 1B). The left atrial diameters of the SR and non-SR patients were				
175	$47.26 \pm 4.06 \text{ mm vs. } 50.20 \pm 3.94 \text{ mm before surgery (P=0.063) and } 46.48 \pm 4.00 \text{ mm vs.}$				
176	48.40±3.84 mm at discharge (P=0.209), showing no statistical difference between the groups.				
177	At the last follow-up, the left atrial diameter was 45.04±3.48 mm in the SR patients vs.				
178	49.60±4.81 mm in the non-SR patients (P=0.004), a statistically significant difference (Figure				
179	2A). The Corresponding changes in MR degree in SR and non-SR patients is shown in Figure				
180	2B.				
181	Clinical Outcomes of AF Combined with Severe AFMR				

All 56 patients in the SAR group completed the valve procedure, CMP IV, and otherconcomitant procedures. Two patients died within 30 days post-surgery due to postoperative

ARDS and pulmonary infection. Postoperative complications included bleeding, low cardiac
output, pulmonary infection, and acute kidney injury. Three cases (5%) required
postoperative electrical cardioversion therapy. At discharge, 50 patients (92.6%) were in SR;
50 cases had no mitral regurgitation and 2 had mild mitral regurgitation. The left atrium
diameter was 48.31±2.60 mm, significantly smaller than pre-surgery (P<0.001), while the left
ventricular end-diastolic diameter (49.41±2.93 mm, P=0.056) and LVEF (54.87±5.46%,
P=0.385) showed no significant changes from pre-surgery.

The mean follow-up period was 2.6±1.1 years. At the last follow-up, 43 patients (79.6%)
in the SAR group maintained SR (KM curve shown in the Figure 3). Echocardiography
showed no mitral regurgitation in 47 cases, mild regurgitation in 4 cases, and moderate
regurgitation in 1 case. The left atrium diameter was 48.46±3.80 mm, significantly smaller
than pre-surgery (P<0.001), while the left ventricular end-diastolic diameter (51.52±3.54 mm,
P=0.225) and LVEF (54.80±4.93%, P=0.310) showed no significant differences from presurgery measurements.

198 Comparison of Perioperative Data between SAR and SPR Groups

The SAR group patients were significantly older and had longer AF durations and more 199 200 preoperative comorbidities than the SPR group. Detailed information is presented in Table 1. In the SAR group, 53 patients underwent mitral valvuloplasty with rings of varying sizes, 201 including 11 patients with No. 28 ring, 24 patients with No. 30 ring, 16 patients with No. 32 202 ring, and 2 patients with No. 34 ring. Three patients underwent mitral valve replacement with 203 bioprosthetic valves. Concomitant procedures included tricuspid valvuloplasty (35 cases), 204 coronary artery bypass grafting (8 cases), and left ventricular outflow tract obstruction (2 205 cases). In the SPR group, 50 patients underwent mitral valvuloplasty with rings of varying 206 sizes, including 10 patients with No. 28 ring, 23 patients with No. 30 ring, 15 patients with 207

No. 32 ring, and 2 patients with No. 34 ring. Six patients underwent mitral valve replacement 208 (3 bioprosthetic and 3 mechanical valves). Concomitant procedures included tricuspid 209 valvuloplasty (19 cases) and coronary artery bypass grafting (2 cases). All patients in both 210 groups completed CMP IV. There was no perioperative mortality in the SPR group. The SAR 211 group had a slightly higher incidence of postoperative complications (Table 2). Fifty patients 212 (92.6%) in the SAR group and 51 patients (91.1%) in the SPR group were in SR at discharge, 213 214 with no significant difference between the groups (P=0.368). At the last follow-up, 43 patients (79.6%) in the SAR group and 49 patients (87.5%) in the SPR group maintained SR. 215 216 The KM curves for the SR maintenance rate showed no statistical difference between the groups (Figure 3A). 217

218 Comparison of Mitral Regurgitation and Cardiac Remodeling Between SAR and SPR
219 Groups

Preoperative echocardiography revealed that in the SAR group, 53 cases were 220 Carpentier type I and 3 were type IIIb MR. In the SPR group, there were 5 cases of 221 Carpentier type I and 51 cases of type II MR. There was no significant difference in left atrial 222 diameter between the groups (P=0.532). The SPR group had a significantly larger left 223 ventricular diameter (P<0.001) and lower ejection fraction (P<0.001) compared to the SAR 224 group. Before discharge, 50 cases in the SAR group had no mitral regurgitation, and 2 had 225 mild regurgitation. In the SPR group, 45 cases had no mitral regurgitation, 4 had mild 226 regurgitation, and 1 had moderate regurgitation. The left atrial diameter in the SAR group 227 was larger than in the SPR group (P<0.001). The ejection fraction in the SAR group was 228 lower than in the SPR group, with no significant difference in left ventricular diameter 229 (P=0.077). At the last follow-up, echocardiography showed that in the SAR group, 47 cases 230 had no mitral regurgitation, 4 had mild regurgitation, and 1 had moderate regurgitation. In the 231

SPR group, 42 cases had no mitral regurgitation, 6 had mild regurgitation, 1 had moderate
regurgitation, and 1 had severe regurgitation. The left atrial diameter in the SAR group
remained larger than in the SPR group (P<0.001), with no significant difference in left
ventricular diameter (P=0.263) and ejection fraction (P=0.001). Detailed data are presented in
Table 3. The changes in MR degree in the SAR and SPR groups are shown in Figure 3B and
3C.

238 Analysis of Risk Factors for Recurrence of AF

239 Cox multivariate analysis indicated that AF recurrence in the MAR group was associated with a lack of regurgitation reduction (HR 0.0369; 95% CI 0.0026-0.5156; 240 P=0.0142), reduction of left atrial diameter (HR 0.01865; 95% CI 0.0007-0.5016; P=0.0177), 241 and was independent of age, CHA2DS2–VASc score, preoperative or postoperative left atrial 242 diameter. In severe MR, the risk factors for AF recurrence in the SAR group included 243 postoperative left atrial diameter greater than 50 mm (HR 4.081; 95% CI 1.109-15.016; 244 P=0.0344), with no association with age, AF duration, CHA2DS2–VASc score, preoperative 245 left atrial diameter, or residual mitral regurgitation. In the SPR group, AF recurrence was 246 associated with a postoperative left atrial diameter greater than 50 mm (HR 12.480; 95% CI 247 1.288-120.898; P=0.0294) and residual mitral regurgitation (HR 16.358; 95% CI 1.604-248 166.850; P=0.0183), with no relation to age, AF duration, CHA2DS2-VASc score, or 249 preoperative left atrial diameter. This study did not identify risk factors for the recurrence of 250 mitral regurgitation in either group. 251

252 Discussion

AF and MR are progressive conditions that exacerbate each other, leading to more
severe symptoms, rapid disease progression, and serious consequences such as heart failure

¹⁰. Timely and effective treatment is particularly important when AF is combined with MR ¹¹.
We selected different treatment strategies based primarily on the degree of mitral
regurgitation, which were all predicated on the treatment of AF. Our data suggests that for
moderate AFMR combined with AF, rhythm control via thoracoscopic AF procedure yields
satisfactory results. Maintenance of SR improves cardiac remodeling and reduces mitral
regurgitation.

For severe AFMR combined with AF, we employed a combination of rhythm control 261 and vavular intervention using the classic CMP IV surgical technique in conjunction with 262 mitral valvuloplasty. This approach aligns with standard surgical guidelines for treating AF 263 combined with severe MR. However, most previous evidence pertains to primary mitral 264 regurgitation combined with AF, not AFMR combined with AF^{12,13}. Our study demonstrates 265 that the safety and efficacy of CMP IV combined with mitral valvuloplasty for severe AFMR 266 with AF are comparable to the outcomes in primary mitral regurgitation with AF. AF is the 267 initiating factor of AFMR, making it the primary target for treatment. In cases of functional 268 mitral regurgitation, merely treating the regurgitation without addressing the primary disease 269 often fails to yield favourable outcomes ¹⁴. In cases of moderate regurgitation, the structural 270 changes in the atrium and mitral valve are reversible ^{15,16}. Although rhythm control may 271 272 reduce or eliminate mitral regurgitation through cardiac remodeling, the efficiency remains unsatisfactory ^{17,18}. The effectiveness of rhythm control is crucial in the management of AF. 273 However, a large proportion of patients with AFMR have long-standing persistent AF, 274 significant left atrium enlargement, high CHA2DS2–VASc scores, and other factors that 275 impede successful treatment or maintenance of SR¹⁹. Previous research has shown that 276 thoracoscopic surgery may be more effective than catheter ablation in SR maintenance 20 . 277 278 The thoracoscopic technique provides high-quality pulmonary vein ablation, directly ablates 279 the Marshall Ligament and autonomic ganglia from the epicardium, and enables left atrial

appendage excision. Our modified procedure includes the isolation of the left atrial posterior
wall to further improve success rates ²¹. Our data shows favourable results for AF patients
with moderate AFMR, although subsequent catheter ablation may be required for patients
with unsuccessful outcomes. This approach is reasonable for AFMR patients who require a
more robust method to maintain SR and interrupt the cycle of AF, MR, and heart failure ²².

Patients with severe AFMR are more challenging to manage for clinicians. We therefore utilized CMP-IV, a classic surgical technique for treating AF, which has the highest single success rate in clinical practice. Despite their increased age, complexity, and potential complications, patients with severe AFMR still require treatment options that offer a high degree success in maintaining SR. As such, these patients would benefit the most from individualized ablation strategies or further minimally invasive procedures.

AFMR is mitral regurgitation secondary to structural or functional abnormalities of the 291 left atrium, leading to mitral annulus enlargement and an imbalance between annulus and 292 leaflet area. Although functional in nature, AFMR may still involve abnormal mitral valvular 293 structure ^{23,24}. Studies suggest that there is potential for mitral valve with structural 294 abnormalities to recover with improved cardiac remodeling ²⁵. However, for most patients 295 with severe AFMR, surgical valvuloplasty is a neccesity due to underlying structural 296 abnormalities ^{26,27}. In patients with AFMR, even with successful AF treament, cardiac 297 remodeling alone may not achieve the necessary changes in the left atrium and mitral valve. 298 From the perspective of AF management, patients with AFMR and AF are often refractory to 299 catheter ablation, thoracoscopic AF procedure, and even hybrid procedures. Therefore, 300 treatment with CMP-IV should be prioritized, as it is more reasonable to undertake 301 concomitant mitral valvuloplasty with its more definitive effect, over over cardiac remodeling 302 with uncertain outcomes in MR²⁸. According to current guidelines, severe MR should be 303

304	treated from a valvular management perspective. Without treatment, residual mitral
305	regurgitation will self-progress and increase the inducibility of AF in the long run ²⁹ .

306 Limitations

While this study addresses an important topic with paucity of data on the impact of 307 therapy, it is constrained by its relatively small sample size and single-centre retrospective 308 309 design. The sample size was limited due to the exclusion of patients with organic mitral valve disease (such as prolapse, flail leaflet, rheumatic disease, or mitral leaflet calcification) and 310 311 the selection of patients with normal left ventricular morphology and function to minimize the interference caused by ventricular functional regurgitation. Propensity scoring matching 312 could not be applied to compare the SAR and SPR groups due to the limited sample size. 313 Patients with AFMR tend to be older, frailer, have more comorbidities, and have experienced 314 AF for a longer duration. These characteristics may not be as apparent after propensity score 315 matching. 316

317 Conclusions

Since AF is the primary cause of AFMR with AF, rhythm control therapy is the cornerstone treatment for these patients. Thoracoscopic AF procedure is an effective and minimally invasive treatment option for patients with AF and moderate AFMR. Moderate AFMR can be potentially reduced by SR restoration, which promotes cardiac remodeling. For patients with severe AFMR and AF, we recommend concomitant CMP-IV with mitral valvuloplasty. This approach is both safe and effective, increasing the success rate of achieving a resolution of both AF and MR.

Acknowledgements: We would like to thank Mr Yuanzhe Ma, Saie Shen M.D., Ms Huihua
Chen and Ms Yu Su for their excellent experimental and clinical support.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.23.24314258; this version posted September 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

References 327

- Gertz ZM, Raina A, Saghy L, et al. Evidence of atrial functional mitral regurgitation 328 1. 329 due to atrial fibrillation: reversal with arrhythmia control. Journal of the American College of Cardiology. 2011;58(14):1474-1481. 330
- Abe Y, Takahashi Y, Shibata T. A new disease entity: Atrial functional mitral 2. 331 regurgitation. Journal of cardiology. 2021;77(6):565-569. 332
- Ito K, Abe Y, Takahashi Y, et al. Mechanism of atrial functional mitral regurgitation 333 3. in patients with atrial fibrillation: A study using three-dimensional transesophageal 334 echocardiography. Journal of cardiology. 2017;70(6):584-590. 335
- Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial 4. 336 337 fibrillation. A population-based study over three decades. The New England journal 338 of medicine. 1987;317(11):669-674.
- 5. Amabile A, Fereydooni S, Mori M, et al. Variable definitions and treatment 339 approaches for atrial functional mitral regurgitation: A scoping review of the 340 341 literature. Journal of cardiac surgery. 2022;37(5):1182-1191.
- Badhwar V, Alkhouli M, Mack MJ, Thourani VH, Ailawadi G. A pathoanatomic 6. 342 approach to secondary functional mitral regurgitation: Evaluating the evidence. The 343 Journal of thoracic and cardiovascular surgery. 2019;158(1):76-81. 344
- Wagner CM, Brescia AA, Watt TMF, et al. Surgical strategy and outcomes for atrial 7. 345 functional mitral regurgitation: All functional mitral regurgitation is not the same! The 346 Journal of thoracic and cardiovascular surgery. 2024;167(2):647-655. 347
- El Sabbagh A, Reddy YNV, Nishimura RA. Mitral Valve Regurgitation in the 348 8. Contemporary Era: Insights Into Diagnosis, Management, and Future Directions. 349 JACC Cardiovascular imaging. 2018;11(4):628-643. 350
- 9. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for Noninvasive 351 Evaluation of Native Valvular Regurgitation: A Report from the American Society of 352 Echocardiography Developed in Collaboration with the Society for Cardiovascular 353 Magnetic Resonance. Journal of the American Society of Echocardiography : official 354 publication of the American Society of Echocardiography. 2017;30(4):303-371. 355
- 356 10. Vavalle JP, Arora S. Atrial Fibrillation: Not an Innocent Bystander in the Treatment of Functional Mitral Regurgitation. JACC Cardiovascular interventions. 357 2020;13(20):2385-2387. 358
- 11. Tamargo M, Obokata M, Reddy YNV, et al. Functional mitral regurgitation and left 359 360 atrial myopathy in heart failure with preserved ejection fraction. European journal of heart failure. 2020;22(3):489-498. 361
- Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the 12. 362 Management of Patients With Valvular Heart Disease: A Report of the American 363 College of Cardiology/American Heart Association Joint Committee on Clinical 364 Practice Guidelines. Journal of the American College of Cardiology. 2021;77(4):e25-365 e197. 366
- Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the 367 13. management of valvular heart disease. European heart journal. 2022;43(7):561-632. 368
- 14. Deferm S, Bertrand PB, Verbrugge FH, et al. Atrial Functional Mitral Regurgitation: 369 JACC Review Topic of the Week. Journal of the American College of Cardiology. 370 2019;73(19):2465-2476. 371
- 372 15. Chen YC, Voskoboinik A, Gerche A, Marwick TH, McMullen JR. Prevention of Pathological Atrial Remodeling and Atrial Fibrillation: JACC State-of-the-Art 373 Review. Journal of the American College of Cardiology. 2021;77(22):2846-2864. 374

375 376 277	16.	Thomas L, Abhayaratna WP. Left Atrial Reverse Remodeling: Mechanisms, Evaluation, and Clinical Significance. <i>JACC Cardiovascular imaging</i> . 2017;10(1):65-
378 379	17.	Soulat-Dufour L, Lang S, Addetia K, et al. Restoring Sinus Rhythm Reverses Cardiac Remodeling and Reduces Valvular Regurgitation in Patients With Atrial
380 381 382	18.	Fibrillation. <i>Journal of the American College of Cardiology</i> . 2022;79(10):951-961. Ganesan AN, Shipp NJ, Brooks AG, et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. <i>Journal of the American</i>
383	10	<i>Heart Association</i> . 2013;2(2):e004549.
384 385	19.	journal of cardiology. 2021;25(5):338-345.
386 387	20.	Castellá M, Kotecha D, van Laar C, et al. Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial. <i>Europace</i> :
388		European pacing, arrhythmias, and cardiac electrophysiology : journal of the
389		working groups on cardiac pacing, arrhythmias, and cardiac cellular
390		electrophysiology of the European Society of Cardiology. 2019;21(5):746-753.
391	21.	Ma N, Ding S, Zeng L, et al. Immediate electrophysiological characteristics following
392		modified thoracoscopic ablation via unilateral approach for non-valvular atrial
393		fibrillation. Heart and vessels. 2021;36(6):874-881.
394	22.	Thomas JD, Raissi SR. Atrial Fibrillation Begets Mitral Regurgitation, or Is it Vice
395		Versa? JACC Cardiovascular imaging. 2019;12(4):678-680.
396	23.	Silbiger JJ. Does left atrial enlargement contribute to mitral leaflet tethering in
397		patients with functional mitral regurgitation? Proposed role of atriogenic leaflet
398		tethering. Echocardiography (Mount Kisco, NY). 2014;31(10):1310-1311.
399	24.	Kihara T, Gillinov AM, Takasaki K, et al. Mitral regurgitation associated with mitral
400 401		annular dilation in patients with lone atrial fibrillation: an echocardiographic study.
402	25	Nishino S. Watanabe N. Ashikaga K. et al. Reverse Remodeling of the Mitral Valve
402	23.	Complex After Radiofrequency Catheter Ablation for Atrial Fibrillation: A Serial 3-
404		Dimensional Echocardiographic Study Circulation Cardiovascular imaging
405		2019·12(10)·e009317
406	26	Luo Y. Zhu Y. Guan X. Lin Y. Assessment of mitral annulus and mitral leaflet in
407	20.	nonvalvular atrial fibrillation patients with various degrees of mitral regurgitation.
408		Real time 3D transesophageal echocardiography <i>Echocardiography (Mount Kisco</i>
409		NY) 2018:35(4):481-486
410	27	Debonnaire P Al Amri I Leong DP et al Leaflet remodelling in functional mitral
411	27.	valve regurgitation: characteristics determinants and relation to regurgitation
412		severity European heart journal Cardiovascular Imaging 2015.16(3):290-299
413	28	Wei K Bao C. Zhao D. Zhang J. Mei J. Ma N. Effectiveness of Maze IV procedure
414	20.	versus thoracoscopic ablation for atrial fibrillation: a propensity score-matched
415		analysis Annals of cardiothoracic surgery 2024:13(2):165-172
416	29	Nakamura K Takagi T Kogame N et al Impact of atrial mitral and tricuspid
417	<i>,</i>	regurgitation on atrial fibrillation recurrence after ablation <i>Journal of</i>
418		electrocardiology 2021:66:114-121
. 10		

421 Figure legend

- 422 Figure 1 Six-year Kaplan-Meier curve for freedom from AF recurrence and comparison of
- 423 mitral regurgitation reduction between SR and non-SR patients.
- 424 Figure 1A. Six-year Kaplan-Meier curve for atrial fibrillation (AF) patients with moderate
- 425 atrial functional mitral regurgitation (AFMR) freedom from AF recurrence. 1B Sinus rhythm
- 426 (SR) maintenance of AF patients with moderate AFMR benefits mitral regurgitation
- 427 reduction (P<0.0001) compared to the non-SR patients.

428

429 Figure 2 Comparison of left atrial diameters between SR patients and non-SR patients and the

430 changes in the degree of mitral regurgitation following thoracoscopic AF procedure.

- 431 Figure 2A. Comparison of left atrial diameters between sinus rhythm (SR) patients and non-
- 432 SR patients with moderate atrial functional mitral regurgitation (AFMR) and atrial fibrillation
- 433 (AF) at different time points (pre-procedure, post-procedure, and at the last follow-up).
- 434 At the last follow-up, the left atrial diameter was 45.04 ± 3.48 mm in SR patients vs.
- 435 49.60±4.81 mm in non-SR patients (P=0.004), a statistically significant difference. 2B. The
- 436 corresponding changes in the degree of mitral regurgitation in SR and non-SR patients with
- 437 moderate AFMR and AF.

438 Figure 3 Kaplan-Meier (KM) curves of SR maintenance rate and the changes in the degree of

- 439 mitral regurgitation following mitral valvuloplasty plus the Cox Maze IV procedure
- 440 Figure 3A. KM curves of sinus rhythm (SR) maintenance rate for severe atrial functional
- 441 mitral regurgitation patients with atrial fibrillation (AF) and severe primary mitral
- 442 regurgitation patients with AF. The KM curves showed no statistical difference between the
- two groups following Cox Maze IV procedure. 3B. the degree of mitral regurgitation in atrial

444	fibrillation (AF) patients with severe atrial functional mitral regurgitation and those with
445	severe primary mitral regurgitation before the procedure.3C the degree of mitral regurgitation
446	in AF patients with severe atrial functional mitral regurgitation and those with severe primary
447	mitral regurgitation after the procedure.
448	
449	
450	
451	
452	
453	
454	
455	
456	
457	
458	
459	
460	

Table 1 Patient Characteristics of three groups. Patients with moderate atrial functional mitral 461

462 regurgitation (AFMR) and atrial fibrillation (AF) (MAR group). Patients with severe AFMR

463 and AF (SAR group). Patients with severe primary mitral regurgitation and AF (SPR group).

Characteristics	MAR(n=33)	SAR (n = 56)	SPR (n = 56)	P- Value(SAR/SPR)	SMD
Age, year, mean ± SD	70.27±6.46	70.54±5.91	66.43±6.39	0.001	0.667
Male (%)	20 (60.61)	37 (66.1)	36 (64.3)	>0.999	0.037
Hypertension (%)	19 (57.58)	42 (75.0)	27 (48.2)	0.007	0.573
Diabetes (%)	10 (30.30)	15 (26.8)	9 (16.1)	0.25	0.263
Previous cerebrovascular accident (%)	3 (9.09)	7 (12.5)	4 (7.1)	0.525	0.181
Coronary artery disease (%)	8 (24.24)	15 (26.8)	6 (10.7)	0.053	0.421
NYHA class III-IV (%)	15 (45.45)	34 (60.7)	38 (67.9)	0.554	0.149
CHA2DS2-VASC Score (median [IQR])	3.00 [3.00,4.00]	3.00 [3.00, 4.00]	2.00 [2.00, 3.00]	0.001	0.647
Duration of AF (median [IQR])	72.00 [48.00,108.00]	66.00 [36.00, 96.00]	60.00 [24.00, 72.00]	0.02	0.465
464					
465					
466					
467					
468					
469					
470					
471					
472					
473					
474					
475					
476					

Table 2 Postoperative complications of patients with severe atrial functional mitral

Postoperative Event	$\mathbf{SAR} \ (\mathbf{n} = 56)$	SPR (n = 56)	P.value
Stroke	2	0	0.495
Pneumonia	6	3	0.489
Poor wound healing	1	0	>0.999
Prolonged ventilation	7	4	0.527
Acute renal failure	4	1	0.364
Blood product transfusion	7	2	0.162
Reoperation for bleeding	1	0	>0.999
New pacemaker	3	1	0.618
Mortality within 30 days	2	0	0.495
Stays, day (median [IQR])	10.00 [9.00, 12.75]	7.00 [7.00, 8.25]	< 0.001

regurgitation and atrial fibrillation (AF) (SAR group) and patients with severe primary mitral regurgitation and AF (SPR group).

495	Table 3 Comparison of cardiac remodeling between patients with severe atrial functional mitral
496	regurgitation and atrial fibrillation (AF) (SAR group) and patients with severe primary mitral
497	regurgitation and AF (SPR group).

Characteristics	SAR $(n = 54)$	SPR (n = 56)	P-Value	SMD
preLAD, mm, mean ± SD	54.61±5.57	53.95±5.22	0.519	0.123
preLVEDD, mm, mean \pm SD	50.61±3.85	56.30±5.84	< 0.001	1.150
preLVEF (%), mean ± SD	55.65±3.77	51.48±4.85	< 0.001	0.960
postLAD, mm, mean \pm SD	48.31±2.60	46.45±3.07	0.001	0.656
postLVEDD, mm, mean \pm SD	49.41±2.93	50.64±4.18	0.077	0.342
postLVEF (%), mean \pm SD	54.87±5.46	49.25±5.87	< 0.001	0.992
fLAD, mm, mean \pm SD	48.46±3.80	46.02±2.94	< 0.001	0.720
fLVEDD, mm, mean ± SD	51.52±3.54	52.29±3.61	0.263	0.214
fLVEF (%), mean ± SD	54.80±4.93	51.27±5.94	0.001	0.646

498 preLAD, pre-operative left atrial diameter; preLVEDD, pre-operative left ventricular end-diastolic

499 diameter; preLVEF, pre-operative left ventricular ejection fraction; postLAD, post-operative left atrial

diameter; postLVEDD, post-operative left ventricular end-diastolic diameter; preLVEF, post-500

501 operative left ventricular ejection fraction; fLAD, follow-up left atrial diameter; fLVEDD, follow-up

left ventricular end-diastolic diameter; fLVEF, follow-up left ventricular ejection fraction 502





